Intelligence · Clinical Development
Pipeline search results
Programs matching “schizophrenia” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 97 pipeline programs matching "schizophrenia" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
RGH-MD-20
Gedeon Richter Plc.
Adolescent Patients (13 to 17 years of age) with Schizophrenia
1 trial -
SPD489
Takeda
Schizophrenia
1 trial -
SPD489 40mg
Takeda
Schizophrenia
1 trial -
SPD489 Low-Dose
Takeda
Negative Symptoms of Schizophrenia
1 trial -
SPD489-335
Takeda
Schizophrenia
1 trial -
TV-44749
Teva Pharma GmbH
Schizophrenia
3 trials -
TV-46000
Teva Pharma GmbH
Schizophrenia
2 trials -
Xanomeline and Trospium Chloride Capsules
Bristol-Myers Squibb Australia Pty Ltd
Schizophrenia
1 trial -
placebo
Pfizer
Schizophrenia
1 trial -
ACP-103
Acadia Pharmaceuticals B.V.
Schizophrenia
1 trial -
ACP-104
Acadia Pharmaceuticals B.V.
Schizophrenia
2 trials -
Bupropion
BRIGHT MINDS BIOSCIENCES INC.
Schizophrenia and Disorders With Psychotic Features
1 trial -
CBD-ESPRIT
The George Institute
Remitted early phase schizophrenia
1 trial -
CET/PT
BRIGHT MINDS BIOSCIENCES INC.
Schizophrenia
1 trial -
CGXV813B12201
Novartis Pharmaceuticals
Schizophrenia
1 trial -
GWP42003-P
Jazz Pharmaceuticals Ireland Limited
Schizophrenia
1 trial -
GlyT-1 inhibitor-1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
1 trial -
Iloperidone crystalline formulation
Vanda Pharmaceuticals Netherlands B.V.
Schizophrenia
1 trial -
LY2140023
Novo Nordisk A/S
Schizophrenia
1 trial -
Lu AE58054
H. Lundbeck A/S
Schizophrenia
1 trial -
Luvadaxistat
NEUROCRINE BIOSCIENCES INC
Schizophrenia
2 trials -
ML-007C-MA
MapLight Therapeutics
Schizophrenia
1 trial -
NBI-1117570
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
NBI-1117570-SCZ2035
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.